上海招聘

 Major Responsibilities

  

• Identify Key Opinion Leaders (KOLs) and establish and maintain scientific relationships with KOLs; connecting KOLs in academic and community centers.
• Act as primary liaison to investigators interested in developing and performing investigator initiated research
• Develop and execute territory plans in alignment with regional and national medical communication plans
• Provide clinical presentations and information in response to unsolicited questions (as appropriate) in academic, community, and healthcare provider setting in both group and one-on-one situations
• Provide medical support to cross functions
• Provide support to clinical development trials from medical affairs perspective
• Provide timely feedback/information on emerging clinical/scientific teams and opportunities to internal stakeholders
• Develop and present internal therapeutic area training modules. Provide congress updates and act as a point of medical/ scientific expertise internally for ad-hoc as well as structured training requests.
• Responds to Health Care Providers requests for clinical / scientific information
• Works in a compliant manner and contributes to the culture of the wider team in up-skilling compliance skills

  

 

  

Qualification

  

• Ability to synthesize recent scientific information, analyze them within strategic and regulatory settings.
• Proven ability to work independently as well as in networks including with internal and external stakeholders.
• Ability to partner and maintain relationships within the medical community
• Excellent communication, presentation and time management skills
• Fluent in spoken and written English is required
• Demonstrated initiative, creativity, strategic capabilities, and ability to work effectively in complex, rapidly changing environments
• Strong project and process building and management skills, along with the ability to work on multiple tasks, and to effectively prioritize.
• Proven team player with ability to navigate cross functionally.
• Values consistent with BeiGene values

百济神州是一家植根中国的全球性商业化生物医药公司，致力于成为分子靶向药物和免疫肿瘤药物研发，及商业创新领域的全球领导者。
2017年，百济神州与新基公司达成战略合作伙伴关系，向新基转让了tislelizumab在美国、欧洲、日本和亚洲以外的其他地区的实体瘤开发和商业化的独家权益，保留了在亚洲（除日本外）开发和商业化tislelizumab用于治疗实体瘤的权益，以及用于治疗恶性血液肿瘤和进行内部组合疗法的全球范围权益。

此外，百济神州获得了新基公司在华获批药物——注射用白蛋白紫杉醇（ABRAXANE？）, 瑞复美（REVLIMID？）和 维达莎（VIDAZA？）的独家授权，并接管其在华商业运营团队。

2018年1月，百济与Mirati公司sitravatinib在亚太地区的独家授权协议，进一步拓宽了公司的产品组合。

截至目前，百济神州在全球各地拥有超过1100名员工，其中包括在中国、美国、澳大利亚和瑞士的超过650名科学家及临床医学专家。

公司在中国的北京、上海、美国的马萨诸塞州Cambridge，新泽西州Fort Lee和加利福尼亚州旧金山Emeryville和San Mateo，瑞士的巴塞尔均设有办事机构。除此之外，百济神州在中国大陆还拥有位于北京的研发中心，苏州、广州两大生产基地，以及在上海的商业运营中心。